Výsledky vyhledávání - "Jerome, Msihid"

Akademický článek

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study

Autor: Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Jerome Msihid, Michel Djandji, Benjamin Ortiz, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Masato Ishida, Kazuhiko Arima

Publikováno v: Allergology International, Vol 72, Iss 1, Pp 89-99 (2023)

Background: Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. Methods: The TRAVERSE open-label extension (OLE) study (NCT02134028) assessed the safety and efficacy of dupilumab 30

Externí odkaz: https://doaj.org/article/a6454e7b2c504233a7b1ee0de552fd38

Zobrazit plný text záznamu

How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations

Autor: Ana Cristina Puga, Catherine Ortemann-Renon, Jeremy N. Ruskin, M. Judith Peterschmitt, Jerome Msihid, Pierre Maison-Blanche, Leorah Ross, Gerald F. Cox

Publikováno v: Molecular Genetics and Metabolism. 131:211-218

Eliglustat is a first-line oral treatment for adults with Gaucher disease type 1 who have cytochrome P450 (CYP) 2D6 extensive, intermediate, or poor metabolizer phenotypes. Per International Conference on Harmonisation (ICH) E14 guidance, a Phase 1 t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0aea3bc1a03800de9be13a659ef8e5
https://doi.org/10.1016/j.ymgme.2020.09.003

Zobrazit plný text záznamu

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Autor: Neil M.H. Graham, Zilberstein Moshe E, Jonathan Sadeh, Vibeke Strand, Cem Gabay, Jerome Msihid, Susan Boklage, Hubert van Hoogstraten, Toshio Kimura, Anita Boyapati, Gerd R Burmester

Publikováno v: Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Arthritis Research and Therapy, Vol. 22, No 1 (2020) P. 70
Arthritis Research & Therapy

Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192a715ed44aff5f653df2a25c9dd684
http://link.springer.com/article/10.1186/s13075-020-02163-6

Zobrazit plný text záznamu

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study

Autor: Yuji Tohda, Yoichi Nakamura, Takao Fujisawa, Motohiro Ebisawa, Jerome Msihid, Michel Djandji, Benjamin Ortiz, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, Masato Ishida, Kazuhiko Arima

Publikováno v: Allergology international : official journal of the Japanese Society of Allergology.

Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma.The TRAVERSE open-label extension (OLE) study (NCT02134028) assessed the safety and efficacy of dupilumab 300 mg every 2 weeks up

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7c645e749d7241434e31d7e2a4d155
https://pubmed.ncbi.nlm.nih.gov/36114102

Zobrazit plný text záznamu

Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma

Autor: Heather F. Burnett, Yingxin Xu, David M. Weinreich, Asif Khan, Siddhesh Kamat, Jerome Msihid, Ian D. Pavord, Eric D. Bateman, Patricia Guyot, Paul Rowe, Jingdong Chao

Publikováno v: RESPIRATORY MEDICINE

Background Currently, five biologic treatment options are available for use in patients with uncontrolled persistent asthma: three interleukin (IL)-5 antagonists, which either bind to the anti-IL-5 ligand (mepolizumab, reslizumab) or to the IL-5 rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53f58f83435e4ab8edebce54ed7d2891
https://biblio.ugent.be/publication/8747035

Zobrazit plný text záznamu

Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study

Autor: Jorge F, Maspero, Guido, Cardona, Patricia, Schonffeldt, Alberto, Tolcachier, Sandra N, González-Diaz, Anahi, Yañez, Clovis E, Galvao, Jerome, Msihid, Rebecca, Gall, Shahid, Siddiqui, Paul J, Rowe, Yamo, Deniz, Juby A, Jacob-Nara, Michel, Djandji

While advances in asthma care have been made in Latin America, there is still a large unmet need in patients with uncontrolled asthma. This post hoc analysis of the QUEST study assessed safety and efficacy of dupilumab in the subgroup of patients enr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2792369a4ed7305544e259207a7ab8

Zobrazit plný text záznamu

Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma

Autor: Jeremy Cole, Yi Zhang, Asif H. Khan, D.J. Lederer, Megan Hardin, Xuezhou Mao, Wanda Phipatanakul, Alessandro Fiocchi, Sandy R. Durrani, Jerome Msihid

Publikováno v: Paediatric asthma and allergy.

Background: Asthma is the most common chronic respiratory condition in children, who may have uncontrolled disease despite maximal therapy. Type 2 (T2) inflammation (blood eosinophils ≥150 cells/µL or FeNO ≥20 ppb) underlies most pediatric asthm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ebdf6930be2a2672ed4215082813d0c
https://doi.org/10.1183/13993003.congress-2021.pa3920

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání